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Scompeting events, such as death from other causes. Such
analyses were precluded by the lack of information on the
cause of death for all patients. Furthermore, the definition
of second primary lung cancer remains controversial. Al-
though the criteria of Martini and Melamed8 are the most
widely used, they may miscategorize some tumors, leading
to inaccuracies in rates of recurrence and second primary
lung cancer. However, it is still crucial to distinguish second
primary tumors from relapse in clinical practice because of
the significant differences in their treatment and prognosis.
Last, surveillance scans were performed at predefined inter-
vals. Recurrences may develop in between CT scans and
clinic appointments. Interval censoring may lead to an over-
estimation of time to event in our analysis.
CONCLUSIONS
Routine CT surveillance detected the majority of recur-
rences, as well as the majority of second primary lung
cancers. We found that the rate of recurrence remained ele-
vated until 4 years after surgery, which is in contrast to the
conventional wisdom. False-positive surveillance scan
results led to subsequent invasive procedures for only 5%
of patients. Most of the second primary lung cancers were
detected at early stages, and more than half of patients un-
derwent surgical resection. On the basis of our results, we
support the use of CT surveillance for survivors of early-
stage NSCLC. However, the optimal interval between sur-
veillance scans remains subject to further study.
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Dr Sean C. Grondin (Calgar, Alberta, Canada). This is an im-
portant article for thoracic surgeons. Many organizations are pub-
lishing guidelines on CT screening, as you mentioned, and it is
a hot topic for discussion. There are a lot of resources at stake,
so I appreciate your group trying to tackle this important question.
I have just a few questions for you. Many patients undergo CT
for follow-up of a nodule, but they are concerned about the radia-
tion exposure. I noticed in your protocol, the first 2 years you were
doing CT scans with contrast and then after that it was CT scans
without contrast. Can you explain to me the justification for using
contrast in the first 2 years? This approach contradicts other CT
screening guidelines by other organizations.
Dr Lou.You mean the justification for using contrast in the first
2 years?
Dr Grondin. Yes, most good CT radiologists will tell you that
you probably do not need contrast and that a CTwithout contrast is
good for screening, so why would you need contrast?
Dr Lou.We used CTwith contrast in the first 2 years because it
may be more effective in identification of hilar or mediastinal
lymph node metastases, as well as liver metastases. However, we
do recognize that the effectiveness of contrast versus noncontrast
CT has not been adequately evaluated in lung cancer surveillance.
In fact, the most recent National Comprehensive Cancer Network
recommendations were changed from CTwith contrast for the first
2 years to CT with or without contrast. The use of contrast in fol-
low-up essentially may make logical sense, but this has not been
validated by large prospective data.
Dr Grondin. Fair enough. I noticed your recurrence rate is
higher than what you would expect from historical series, 6% to
10%. Can you explain to me why that might be in your series?
Is this a reflection of the staging of the patients before they under-
went operation, they were not fully staged, or why is this higher in
your group do you think?
Dr Lou. I am not sure if the recurrence rate found in our group
was actually higher than in other series. The traditionally quoted
5-year recurrence rate of stage I disease is 20% to 39%. We found
that 20% of patients developed recurrences. But one thing we did
that was different was that in addition to looking at only the pro-
portion of recurrence over time, we looked at the rate of recur-
rence-meaning events over the number of months followed
within each 12-month interval, and that is the recurrence rate
we found.
Dr Grondin. The next question I have pertains to imaging of
patients for follow-up. If we all agree that CT is pretty good, and
down deep in my heart I think that CT probably is better than chestardiovascular Surgery c Volume 145, Number 1 81
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be even better than CT?
Dr Lou. Although PET scan has not been part of any of the or-
ganizations’ guidelines for surveillance, it recently has been inves-
tigated by some groups in Korea and the United States. The last
study that I found actually gave patients both CT scan and PET sur-
veillance, and they found that the PET scan was able to detect
a few percentages more of recurrences, most of which were distal.
However, when compared with CT scans, PET scans also missed
a few cases, especially when these masses are localized to the
lung if they were small or ground-glass opacities. So there are
pluses and minuses of PET scans, and I think more studies are war-
ranted in this area. But one must be cautious in interpreting these
studies, because the question of which is the superior modality
should be the actual effect on survival and patient-oriented out-
comes instead of only slight improvement in detection sensitivity.
Dr Grondin. My last question has to do with survival. That is
the elephant in the room. It is great to do imaging studies such
as CT, but at the end of the day is there any improvement in sur-
vival? I noticed that approximately three quarters of your patients
had distant metastases detected by CT. I am not aware of any data
that treating this subgroup of patients significantly extends sur-
vival. What are your thoughts on whether this early detection of re-
current disease with CT will translate into a survival advantage?
DrLou. This is something we thought of extensively as a group.
Again, there have been no prospective randomized trials looking at
the exact effect of earlier detection by surveillance programs.
However, at least for second lung primaries from our studies and
some previous series, you can see that most of them were able to
be detected in the early stage when curative therapies could be
given. It could be inferred that this kind of early detection would
lead to a survival benefit in those with a second primary tumor,
but again prospective verification is needed. However, it is more
controversial when you are talking about recurrences because
most patients with recurrences can only receive palliative therapy,
so the question of whether that kind of therapy would be more ben-
eficial if given a few months or weeks before would actually affect
long-term survival is more controversial and definitely needs to be
studied.We should not make a judgment on that before prospective
studies are done.
Dr Grondin. Thank you, and great job.82 The Journal of Thoracic and Cardiovascular SurgeDrRobert Shen (Rochester, Minn). I noted that 25% of patients
with a second primary lung cancer were treated with external beam
radiation therapy rather than surgical resection. Do you have
a sense of how many of those patients were medically ineligible
or thought to be medically ineligible for further surgery or were
offered surgery and refused? A corollary to that is what is your
institutional algorithm for a patient who is thought to have a second
primary? Is the patient offered surgery as the first treatment or is it
thought to be equivalent to offer stereotactic radiation?
Dr Lou. With regard to second primary lung cancers, it is al-
ways interesting to look at the outcomes and their treatments.
We do not have the exact numbers and the exact reasons why these
patients received surgery versus another treatment; however, I
would suspect a lot of these patients having undergone one surgical
resection already may have limited physiologic and respiratory re-
serve, which may limit their ability to undergo surgery, but that is
just a general sense of what I think happened. In terms of how the
decision was made exactly in each case, it was most likely depen-
dent on each radiologist and surgeon, but it is our institution’s prac-
tice that whenever a second primary lung cancer is detected, the
best alternative should be surgical resection if tolerated.
Dr Frederic Grannis (Duarte, Calif). This is the second of 2
important articles presented during this meeting on metachronous
lung cancer, and, although they are single institution reviews,
when those single institutions are Mayo Clinic and Memorial
Sloan Kettering, people have to pay close attention. I think yours
is the stronger study because it relies on a defined diagnostic reg-
imen, and I think the evidence is stronger, but I have a problem.
Your second author, Dr Peter Bach, authored an article in The
Journal of the American Medical Association last month in which
he published lung cancer screening guidelines for the American
College of Chest Physicians and American Society of Clinical
Oncology. In those guidelines he ignored his own data presented
today by omitting this important ultra-high risk group of people
from lung cancer screening guidelines. I think this will have
adverse consequences and that lives will be lost because of that
omission. So when you return to New York City, please ask
Dr Bach why he omitted his own data in writing the American
College of Chest Physicians and American Society of Clinical
Oncology guidelines.
Dr Lou. Thank you.ry c January 2013
